Post hoc analysis of a 52-week randomised withdrawal trial in bipolar I disorder: 73.5% on aripiprazole once-monthly 400 mg vs 48.9% on placebo stayed free of any mood episode recurrence (NNT 5); discontinuation for adverse events was 17.4% vs 25.6%.
Secondary analysisn = 265
Citrome et al. Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed